Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China
- 1 April 2021
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 48 (2) , 141-144
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (71774005)
This publication has 11 references indexed in Scilit:
- Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysisBMJ, 2019
- Cancer drugs in LMICs: cheap but unaffordableOncotarget, 2017
- Obstacles and opportunities in Chinese pharmaceutical innovationGlobalization and Health, 2017
- Inequalities in lung cancer: a world ofEGFREuropean Respiratory Journal, 2016
- Cancer drug development in China: recent advances and future challengesDrug Discovery Today, 2015
- Public funding and private investment for R&D: a survey in China’s pharmaceutical industryHealth Research Policy and Systems, 2014
- Icotinib: kick-starting the Chinese anticancer drug industryThe Lancet Oncology, 2013
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialThe Lancet Oncology, 2013
- Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studiesLung Cancer, 2012
- Innovative drug R&D in ChinaNature Reviews Drug Discovery, 2011